Evidence map›Paper›PMID 41655532›Full record

ArticleBreast (Edinburgh, Scotland)2026

Impact of axillary disease extent defined by baseline

Cornelis M de Mooij, Janine M Simons, Florien J G van Amstel, Cristina Mitea, Paul J van Diest, Patty J Nelemans, Felix M Mottaghy, Carmen C van der Pol, Ernest J T Luiten, Linetta B Koppert and 3 more

Abstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cornelis M de MooijDepartment of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Janine M SimonsDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Florien J G van AmstelDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands. Electronic address: florien.vanamstel@maastrichtuniversity.nl.
Cristina MiteaDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Paul J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Patty J NelemansDepartment of Epidemiology, Maastricht University, Maastricht, the Netherlands.
Felix M MottaghyDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany.
Carmen C van der PolDepartment of Surgical Oncology, Alrijne Hospital, Leiderdorp, the Netherlands.
Ernest J T LuitenDepartment of Surgery, Amphia Hospital Breda, Breda, the Netherlands; Department of Surgery, College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi Emirate, Al Ain, United Arab Emirates.
Linetta B KoppertDepartment of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Marjolein L SmidtDepartment of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Thiemo J A van NijnattenDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
REFINE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn clinically node-positive patients, sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and combined SLNB/MARI (RISAS-procedure) can replace axillary lymph node dissection (ALND) after neoadjuvant systemic therapy. Surgical staging outcome can be combined with baseline axillary disease on

methodIncluded were patients with baseline

resultsOf 185 patients, 116 had limited and 69 had advanced baseline axillary disease. Staging-procedures had higher accuracy in limited than advanced baseline axillary disease. When the RISAS-procedure detected residual disease, the probability of remaining positive nodes at cALND was lower in limited than advanced baseline axillary disease (44.9% vs. 91.5%,p < .001). When SLNB or MARI detected residual disease, the probability of remaining positive nodes at cALND was >88.4%, irrespective of baseline axillary disease.

conclusionStaging-procedures had higher accuracy in patients with limited than advanced axillary disease on baseline

Indexed as

Breast NeoplasmsLymph NodesPositron Emission Tomography Computed TomographyAdultAgedAxillaFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualNeoplasm StagingRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals(18)F-FDG PET/CTAxillary lymph nodesBreast cancerNeoadjuvant chemotherapy

Identifiers

PMID41655532
PMCPMC12907496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.